The VESALIUS-CV study tested evolocumab in 12,257 patients at high cardiovascular risk who had never had a heart attack or stroke.[1][3] Patients were randomly divided into two groups - one receiving evolocumab and the other placebo - and were followed for an average of 4.6 years.[3][6] The results showed that evolocumab reduced the risk of a first heart attack, stroke, or death from coronary disease by 25 percent compared to placebo.[1][3] Patients taking evolocumab also had a 36 percent reduction in the risk of myocardial infarction.[3] The drug lowered LDL cholesterol by 55 percent, reaching an average of 45 mg/dL compared to 115 mg/dL at the start of the study.[1][2] The study showed that evolocumab is effective in the primary prevention of cardiovascular diseases, i.e. in patients without previous cardiovascular events.[1][4] The results were published in the New England Journal of Medicine and presented at the American Heart Association conference in November 2025.[1][3]